Loading...
Symbols:
Get Seeking Alpha Free Stock Alerts by Email!
Get Free Stock Alerts by Email!
Transcripts
- Alnylam Pharmaceuticals, Inc. Q3 2008 Earnings Call Transcript
- eHealth, Inc. Q3 2008 Earnings Call Transcript
- MIPS Technologies, Inc. F1Q09 (Qtr End 09/30/08) Earnings Call Transcript
- Alexza Pharmaceuticals, Inc. Q3 2008 Earnings Call Transcript
- Alkermes, Inc. F2Q09 (Qtr End 09/30/08) Earnings Call Transcript
- Akorn, Inc. Q3 2008 Earnings Call Transcript
- Energy XXI (Bermuda) Limited F1Q09 (Qtr End 09/30/08) Earnings Call Transcript
- The Advisory Board Company F2Q09 (Qtr End 09/30/08) Earnings Call Transcript
- Thomas Weisel Partners Group, Inc. Q3 2008 Earnings Call Transcript
- The9 Q3 2008 Earnings Call Transcript
-
Editors' Picks
-
Most Popular
- General Electric: Genuine Risk of Collapse?
- Food: Against Self-Sufficiency
- The Fed: Now the World's Largest Private Bank
- Key to the Global Equity Market: Trend and Cycle Analysis of U.S. Retail
- Can a Global Economy Be Managed One Nation at a Time?
- Global Markets Week in Review: Turbulent Times
- Full list of Editors' Picks »
- Jim Rogers on China »
- Memo to Warren: AmEx Preferred at 15%, Warrants at $12 »
- Should We Really Bail Out the Big Three Automakers with $73.20 Per Hour Labor? »
- Peak Oil's Bell Is Ringing »
- UltraShort ETFs: At a Tipping Point? »
- The Biggest Problem Detroit's Big Three Face »
- 11 Stocks Selling Below Cash »
- Tech May Be a Wreck, But This Isn't 2001 »
- The Autos and Mentality That Ruined Detroit »
- Iceland: What It's Like to Live in a World Without Money »
- Wall Street Breakfast: Must-Know News »
Hedge Fund Jobs
Job Seekers: Search jobs by category, get job alerts by email or live feed, apply online See full list of jobs »
Employers: See all recruitment options, get applications online or by email Post a job »
User 142431
1 Comment
Elan, Biogen Idec Won't Gain Much from Tysabri Approval
Tysabri's run rate is already higher than suggested in your article. The incidence of PML in Tysabri monotherapy is exactly 0. Assuming your figure of 500,000 with Crohns is correct, this represents a potential market of $14.5 billion, not $800 million.
Let's hope your readers decide to dig a little deeper. You certainly did not.